T1	Participants 78 158	patients with initial symptoms of prostatic adenoma and risk of its progression]
T2	Participants 218 246	multicenter, open-population
T3	Participants 342 441	50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls.
